Herpesviruses can either cause primary infection or may get reactivated after both hematopoietic cell and solid organ transplantations. In general, viral infections increase post-transplant morbidity and mortality. Prophylactic, preemptive, or therapeutically administered antiviral drugs may be associated with serious side effects and may induce viral resistance. Virus-specific T cells represent a valuable addition to antiviral treatment, with high rates of response and minimal side effects. Even low numbers of virus-specific T cells manufactured by direct selection methods can reconstitute virus-specific immunity after transplantation and control viral replication. Virus-specific T cells belong to the advanced therapy medicinal products, and their production is regulated by appropriate legislation; also, strict safety regulations are required to minimize their side effects.

Department of Experimental Biology Faculty of Science Masaryk University Kamenice 5 625 00 Brno Czechia; International Clinical Research Center St Anne's University Hospital Brno Pekarska 53 656 91 Brno Czechia

Department of Experimental Biology Faculty of Science Masaryk University Kamenice 5 625 00 Brno Czechia; International Clinical Research Center St Anne's University Hospital Brno Pekarska 53 656 91 Brno Czechia; Department of Histology and Embryology Faculty of Medicine Masaryk University Kamenice 3 625 00 Brno Czechia

Department of Histology and Embryology Faculty of Medicine Masaryk University Kamenice 3 625 00 Brno Czechia; Institute of Hematology and Blood Transfusion Cell Therapy Department U Nemocnice 2094 1 128 00 Prague 2 Czechia

Institute of Hematology and Blood Transfusion Cell Therapy Department U Nemocnice 2094 1 128 00 Prague 2 Czechia

International Clinical Research Center St Anne's University Hospital Brno Pekarska 53 656 91 Brno Czechia; Department of Histology and Embryology Faculty of Medicine Masaryk University Kamenice 3 625 00 Brno Czechia

Citace poskytuje Crossref.org